| Date | Title | Description |
| 27.02.2024 | Germfree Announces the Appointment of Four Independent Board Members | Feb 27 2024
Ormond Beach, Florida – Germfree announces the appointments of Dorothy Puhy, Karen Flynn, Kerry Ingalls and Helga Salling as independent non-executive members of its Board of Directors.
“We are excited to welcome Dorothy, Kare... |
| 27.10.2023 | EW Healthcare Partners Acquires Stake in Boiron Group, a Leader in Natural Medicine | Oct 27 2023
LONDON, England—(Newswire.com)—EW Healthcare Partners announced that it has acquired a c. 25% minority stake in Boiron Developpement, an entity formed for the purposes of launching a tender offer for the Boiron Group, in partne... |
| 18.07.2023 | VitalConnect Secures over $30 Million in Oversubscribed Series F Financing | Jul 18 2023
New funding to accelerate company’s strong commercial momentum
SAN JOSE, California—(BUSINESS WIRE)—VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced closing on an oversubsc... |
| 28.06.2023 | Grundium Oy Announces the Appointment of Head of the US Business and Two Independent Board Members | Jun 28 2023
TAMPERE, Finland – Grundium Oy announced today the appointments of Joshua Griffith as head of the US operations and Andy Thomson and Chris Linthwaite as independent non-executive members of its Board of Directors, effective Jun... |
| 18.05.2023 | EW Healthcare Partners Announces Platform Investment in Enercon Technologies | May 18 2023
Leading electronics-focused design, engineering, and product manufacturing capabilities position Enercon for continued growth in medical devices and life sciences
Leading electronics-focused design, engineering, and product ma... |
| 14.12.2022 | Frost & Sullivan Recognizes VitalConnect with the 2022 New Product Innovation Award for Its Leading-edge Wearable Patient Monitoring Device | Dec 14 2022
VitalConnect delivers a cost-effective, 24/7 remote patient monitoring platform that outperforms existing patient monitoring devices on the market.
SAN ANTONIO, Texas —— Based on its recent analysis of the wearable biosensor i... |
| 01.11.2022 | BioTissue Completes Name Change | Nov 01 2022
MIAMI,Florida — BioTissue Holdings Inc., announced today the completion of its name change from TissueTech, Inc. The change is part of a corporate-wide branding initiative launched earlier this year to better represent the comp... |
| 18.10.2022 | EW Healthcare Partners Acquires Germfree Laboratories, Inc. | Oct 18 2022
Manufacturer positioned to deliver solutions to ease space constraints in the fast-growing cell and gene therapy sector.
New York, NY, and Ormond Beach, FL – EW Healthcare Partners announced today that it has acquired Germfree... |
| 12.09.2022 | VitalConnect Announces Investment from HCA Healthcare to Accelerate Commercial Growth and Create Strategic Partnership | Sep 12 2022
Strategic Investment Expected to Help Accelerate Cardiac Monitoring and Strategic Relationship Aims to Create Improved Disease State Treatment Models
SAN JOSE, California—(BUSINESS WIRE)—VitalConnect®, Inc., a leader in remote... |
| 16.08.2022 | VitalConnect Appoints Amy Covert as Chief Financial Officer | Aug 16 2022
Addition of Experienced Financial Leader Bolsters Strong Management Team
SAN JOSE, California—(BUSINESS WIRE)—VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced the appointme... |
| 09.08.2022 | VitalConnect Announces Addition of Heather Getz to Board of Directors | Aug 09 2022
Getz adds 25 Years of Financial and Healthcare Leadership to Growing Company
SAN JOSE, California—(BUSINESS WIRE)—VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced the addit... |
| 15.07.2022 | EyePoint Pharma Shares Rise 19% After Positive Data for EYP-1901 Trial | Jul 15 2022
WATERTOWN, Massachusetts—/PRNewswire/—EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders,... |
| 31.05.2022 | TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to Acquire TherapeuticsMD | May 31 2022
BOCA RATON, Fla. —TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has entered into a definitive merger agreement to be ... |
| 05.05.2022 | EW Healthcare Partners Announces the Acquisition of a Majority Stake in Grundium Oy | May 05 2022
LONDON (Newswire.com) - EW Healthcare Partners (“EW”) has acquired a majority stake in Grundium Oy (“Grundium”), a leader in advanced imaging technology based in Finland. The founders and management of Grundium will retain a si... |
| 18.03.2022 | Recordati Completes the Acquisition of EUSA Pharma | Mar 18 2022
MILAN, Italy—Following the positive outcome of the regulatory clearances process, Recordati announces today the closing of the previously announced acquisition of EUSA Pharma (UK) Ltd(1), a global specialty pharmaceutical compa... |
| 27.01.2022 | Ted Davis to Succeed Amy Tseng as President and CEO of TissueTech | Jan 27 2022
MIAMI—(BUSINESS WIRE)—TissueTech, Inc., a pioneer in the clinical application of cryopreserved human birth tissue products to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions, has named... |
| 10.01.2022 | VitalConnect Announces Closure of $39 Million Round of Growth Financing | Jan 10 2022
Series E Financing led by EW Healthcare Partners with Robert S White to Join Board
SAN JOSE, California —— VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced the completion o... |
| 20.10.2021 | Laboratoires Majorelle appoints Alexandre de Germay as Chief Executive Officer | Oct 20 2021
PARIS, France—Laboratoires Majorelle, a fast-growing French specialty pharma company focused on prescription and OTC products in women’s health and urology, today announces the appointment of Alexandre de Germay as Chief Execut... |
| 04.10.2021 | EW Healthcare Partners Announces the Promotion of Senior Executives | Oct 04 2021
NEW YORK, New York – EW Healthcare Partners (“EW”), a leading healthcare growth equity firm with a global investment practice, has announced the promotion of senior executives of their investment team.
• Brooks Andrews has bee... |
| 30.04.2021 | EW Healthcare Partners Announces the Acquisition of a Majority Stake in Laboratoires Majorelle | Apr 30 2021
London, UNITED KINGDOM—EW Healthcare Partners (“EW”) has acquired a majority stake in Laboratoires Majorelle (“Majorelle”) from its Founders to support its growth and European expansion in line with the Founders’ strategy.
Hea... |
| 30.03.2021 | Bioventus Acquires Bioness, Inc. | Mar 30 2021
DURHAM, North Carolina –– Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has acquired Bioness, Inc. (“Bioness”), a global leader in neuromodulation and rehabilita... |
| 29.03.2021 | Charles River Laboratories Completes the Acquisition of Cognate BioServices | Mar 29 2021
WILMINGTON, Mass.—(BUSINESS WIRE)—Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Cognate BioServices, Inc. for approximately $875 million... |
| 17.02.2021 | Charles River Laboratories to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development | Feb 17 2021
– Significantly Expands Charles River’s Scientific Capabilities in the High-Growth Cell and Gene Therapy Sector –
– Combines Cognate’s Comprehensive Cell and Gene Therapy CDMO Capabilities to Establish an Integrated Solution f... |
| 10.02.2021 | Bioventus Announces Pricing of Initial Public Offering | Feb 10 2021
DURHAM, North Carolina(GLOBE NEWSWIRE)—Bioventus Inc. (“Bioventus” or the “Company”) today announced the pricing of its initial public offering of 8,000,000 shares of Class A common stock at a public offering price of $13.00 pe... |
| 28.01.2021 | EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD | Jan 28 2021
WATERTOWN, Massachusetts (GLOBE NEWSWIRE)—EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye d... |
| 20.01.2021 | EW Healthcare Partners Announces the Closing of EW Healthcare Partners Acquisition Fund with Bioventus as the Core Holding | Jan 20 2021
New York, NY –– EW Healthcare Partners (“EW”), a private equity firm dedicated to making growth equity investments in rapidly growing healthcare companies, announced the closing of EW Healthcare Partners Acquisition Fund (“EW-A... |
| 20.01.2021 | Haemonetics To Acquire Cardiva Medical, Inc. To Expand Hospital Portfolio | Jan 20 2021
BOSTON, Massachusetts—PRNewswire—Haemonetics Corporation (NYSE: HAE) (“Haemonetics”), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that... |
| 12.08.2020 | Molecular Partners Announces Agreement with Swiss Government, Securing Rights to Purchase Doses of First Anti-COVID-19 DARPin® Program | Aug 12 2020
· Swiss Government will pay a reservation fee for the right to purchase up to 3.2 million doses of anti-COVID-19 DARPin® candidate, MP0420, for both therapeutic and potential prophylactic use
· Purchase of these doses may occu... |
| 14.07.2020 | Cardiva Medical Announces $45 Million Financing Led by EW Healthcare Partners | Jul 14 2020
Robert S. White Joins Board of Directors
SANTA CLARA, California (GLOBE NEWSWIRE)—Cardiva Medical, Inc, an innovator in the field of vascular closure, today announced the completion of a $45 million equity financing round. The... |
| 02.07.2020 | MiMedx Announces Concurrent $150 Million Private Equity and Debt Financings | Jul 02 2020
Equity Financing Led by EW Healthcare Partners and Debt Financing Provided by Hayfin Capital Management. EW Healthcare Partners Managing Director and Co-Founder Martin Sutter and Former Medtronic Chairman and CEO William Hawkin... |
| 16.06.2020 | Cobra Biologics signs supply agreement with AstraZeneca for manufacture of COVID-19 vaccine candidate | Jun 16 2020
Providing large scale manufacturing capacity for AZD1222
Keele, UK, 16 June 2020: Cobra Biologics (Cobra), part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, today announced it has... |
| 30.04.2020 | Xenex LightStrike Robot Destroys SARS-CoV-2 (Coronavirus) in 2 Minutes; First & Only UV Disinfection Technology Proven to Deactivate COVID-19 Virus | Apr 30 2020
San Antonio – April 30, 2020 — SARS-CoV-2 is a global threat for which the world was unprepared. Xenex Disinfection Services announced today that its LightStrike™ pulsed xenon disinfection robot is the first and only ultraviole... |
| 21.02.2020 | EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock | Feb 21 2020
Watertown, MASSACHUSETTS—(GLOBE NEWSWIRE)—EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products today announced the pricing of an u... |
| 21.01.2020 | Cognate BioServices closes Series B and completes acquisition of Cobra Biologics | Jan 21 2020
MEMPHIS, Tennessee—Cognate BioServices, a leading contract development and manufacturing organization (CDMO) specialized in cell and cell-mediated gene therapy products today announced that it has completed the acquisition of C... |
| 06.01.2020 | Sonendo® Announces Growth Investment from EW Healthcare Partners | Jan 06 2020
Leading Dental Technology Company Raises $85 Million to Accelerate Growth
LAGUNA HILLS, California—Sonendo, Inc., a leading dental technology company, announced today that EW Healthcare Partners, a global healthcare growth equ... |
| 13.12.2019 | TELA Bio Announces Closing of Initial Public Offering of Common Stock | Dec 13 2019
MALVERN, Pennsylvania—TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs ... |
| 06.12.2019 | TELA Bio Awarded Contract with HealthTrust Purchasing Group | Dec 06 2019
MALVERN, Pennsylvania—TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs ... |
| 29.11.2019 | Knight Therapeutics Announces Closing of Previously Announced Acquisition of Grupo Biotoscana | Nov 29 2019
MONTREAL, Canada—Knight Therapeutics Inc. (TSX: GUD) (“Knight”) today announced that it has completed the acquisition of a 51.2% interest in Biotoscana Investments S.A. (B3: GBIO33) (“GBT” or “Grupo Biotoscana”) from a controll... |
| 05.10.2019 | Sonendo Named to Inc. 5000 List of Fastest-Growing Private Companies | Oct 05 2019
LAGUNA HILLS, California—Inc. magazine today revealed that Sonendo®, developer of the GentleWave® System, is No. 19 on its annual Inc. 5000 list of the nation’s fastest-growing private companies.
“It is an honor to be named to... |
| 26.08.2019 | Cognate BioServices Secures Growth Capital Investment from EW Healthcare to Continue to Expand Commercial Manufacturing Capacity and Services for the Cellular Therapies Industry | Aug 26 2019
BALTIMORE & MEMPHIS, Tennessee –(BUSINESS WIRE)–Cognate BioServices, a leading contract development and manufacturing organization (“CDMO”) in the global cellular therapies industry, announced today it has secured a financi... |
| 22.08.2019 | EW Healthcare Partners Raises Over $745 Million Fund 2 | Aug 22 2019
Team of Experienced Healthcare Investors and Former Healthcare Executives Will Invest in Select Healthcare Companies to Seek to Accelerate Their Revenue Growth
Partner and Principals Promoted in London, New York and Palo Alto ... |
| 08.07.2019 | LightStrike Robot Proven Effective at Destroying Deadly Superbug Candida auris in New Published Study | Jul 08 2019
SAN ANTONIO—(BUSINESS WIRE)—Candida auris (C.auris) is an emerging, often multi-drug resistant, fungus that causes serious and often deadly infections in healthcare settings. The Centers for Disease Control & Prevention (CD... |
| 01.07.2019 | EyePoint Pharmaceuticals Added to Russell 3000® and 2000® Indexes | Jul 01 2019
WATERTOWN, Massachusetts—(GLOBE NEWSWIRE)—EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) (“Eyepoint”), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today annou... |
| 26.06.2019 | TissueTech Raises $82 Million in Latest Round of Equity Financing | Jun 26 2019
EW Healthcare Partners Managing Director Martin Sutter and Former Medtronic CEO Bill Hawkins join TissueTech Board of Directors
(PRWEB) MIAMI, Florida—TissueTech, Inc., the pioneer in regenerative medicine utilizing human umbi... |
| 02.04.2019 | Encore Dermatology Inc. Acquires SERNIVO®, TRIANEX® and PROMISEB®. | Apr 02 2019
MALVERN, Pennsylvania—Encore Dermatology Inc. announced today that it has acquired rights for SERNIVO® (betamethasone dipropionate) Spray, 0.05%, as well as rights to market and distribute TRIANEX® 0.05% (Triamcinolone Acetonid... |
| 15.03.2019 | Restoration Robotics and Venus Concept Announce Merger to Create a Leading Global Medical Aesthetics Company | Mar 15 2019
SAN JOSE, California and TORONTO, (GLOBE NEWSWIRE)—Restoration Robotics, Inc. (“Restoration Robotics”) (HAIR), a global leader in robotic hair restoration, and Venus Concept Ltd. (“Venus Concept”), a privately-held global aesth... |
| 05.03.2019 | Patricia Altavilla Appointed as Chief Executive Officer at Suneva Medical | Mar 05 2019
Company Advances into Next Phase of Regenerative Aesthetics with Industry Veteran
SAN DIEGO, California—Suneva® Medical, Inc., privately held aesthetics company, announces Chief Executive Officer, Patricia Altavilla as success... |
| 20.02.2019 | Mayo Clinic Study Reports 47% Reduction in C.diff Infection Rates Using Pulsed Xenon UV Room Disinfection | Feb 20 2019
SAN ANTONIO, Texas—Clostridioides difficile (C.diff) is a serious and highly contagious intestinal infection that can cause diarrhea, colitis and even death. Even with the world’s most robust infection prevention strategy and p... |
| 08.01.2019 | Vestar-backed Healthgrades Buys Influence Health | Jan 08 2019
Healthgrades, a Vestar Capital Partners portfolio company, said Jan. 8 that it acquired Influence Health. Financial terms weren’t announced. Influence Health, of Birmingham, Alabama, provides patient engagement software and hea... |
| 27.11.2018 | Gurnet Point Capital Completes Tender Offer for Corium International, Transaction Valued in Excess of $500 Million | Nov 27 2018
CAMBRIDGE, Mass.—(BUSINESS WIRE)—Gurnet Point Capital (“Gurnet Point”), a private investment firm focused on the healthcare and life sciences sectors, announced today that it has completed the previously announced tender offer ... |
| 19.11.2018 | Axogen Advances its Platform for Nerve Repair at Annual Analyst and Investor Day | Nov 19 2018
Updates Value of the Market Opportunity in Existing Applications from $2.2 Billion to $2.7 Billion
Announces Market Development and Clinical Initiatives for Expanded Application in the Surgical Treatment of Chronic Neuropathic... |
| 29.10.2018 | Avance Nerve Graft Receives Regenerative Medicine Advanced Therapy (RMAT) Designation | Oct 29 2018
RMAT Designation reinforces clinical significance of RANGER® registry data and acknowledges the unmet need for improved nerve repair solutions
ALACHUA, Florida—(GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ: AXGN), a global leader in d... |
| 15.10.2018 | EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg | Oct 15 2018
The first long-lasting, FDA approved micro-insert for up to three years of continuous control in chronic, non-infectious posterior segment uveitis, the third leading cause of blindness in the US
WATERTOWN, Mass., October 15, 2... |
| 11.10.2018 | Corium Announces Agreement for Gurnet Point Capital to Purchase All Outstanding Shares | Oct 11 2018
Total Transaction Valued in Excess of $500 Million, Representing a 50% Premium
Gurnet Point Capital to Expand Operations While Focusing on the Approval and Commercialization of Corium’s Corplex Donepezil
MENLO PARK, Californi... |
| 10.10.2018 | EW Healthcare Partners Announces the Appointment of Two Senior Executives | Oct 10 2018
NEW YORK, New York – EW Healthcare Partners (“EW”), a leading healthcare growth equity firm with a global investment practice, has announced the addition of two senior executives to their investment team:
• Olivier Bohuon, for... |
| 18.07.2018 | EUSA Pharma Announces Acquisition of Global Rights to SYLVANT (siltuximab) from Janssen Sciences Ireland UC for $115 Million | Jul 18 2018
HEMEL HEMPSTEAD, England – – EUSA Pharma (EUSA), a biopharmaceutical company focused on oncology and rare diseases, announced today that it has entered into a definitive agreement with Janssen Sciences Ireland UC, a subsidiary ... |
| 08.06.2018 | AxoGen Chairman and CEO Karen Zaderej Named Entrepreneur of the Year 2018 Award Winner in Florida | Jun 08 2018
ALACHUA, Florida—(GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that Ernst & Young (EY) named AxoGen Chairman an... |
| 09.05.2018 | AxoGen, Inc Announces Upsizing and Pricing of Public Offering of Common Stock | May 09 2018
ALACHUA, Florida (GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, announced today that it has priced an underwritten public offering o... |
| 01.05.2018 | Encore Dermatology, Inc. Announces the Launch of IMPOYZ (clobetasol propionate) Cream, 0.025%, a Newly Formulated High-Potency Topical Corticosteroid | May 01 2018
MALVERN, Pennsylvania—Encore Dermatology Inc. announces today the availability of a new topical product, IMPOYZ Cream, indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. IMP... |
| 28.03.2018 | pSivida Corp. Announces Transformative Acquisition of Icon Bioscience Inc. and Growth Capital Financing with Essex Woodlands Healthcare Partners - Company will Rebrand as EyePoint Pharmaceuticals, Inc... | Mar 28 2018
WATERTOWN, Massachusetts(GLOBE NEWSWIRE)—pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the acquisition o... |
| 07.03.2018 | EUSA Pharma Appoints Industry Veteran Rolf K Hoffmann to its Board of Directors | Mar 07 2018
HEMEL HEMPSTEAD, England –– EUSA Pharma (EUSA), a world-class specialty pharmaceutical company focused on oncology and oncology supportive care, today announced the appointment of Rolf K Hoffmann to its Board of Directors. Mr H... |
| 21.02.2018 | Cota Announces $40 Million Series C Financing to Advance Classification System | Feb 21 2018
NEW YORK, NY—Cota Inc., a healthcare real-world evidence and data analytics company bridging precision medicine to population health, today announced the completion of a Series C round of financing led by IQVIA (NYSE:IQV) with ... |
| 15.11.2017 | AxoGen, Inc. Announces Proposed Public Offering of Common Stock | Nov 15 2017
ALACHUA, Florida—(GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the repair of peripheral nerve damage, announced today that it has commenced an underwr... |
| 15.11.2017 | EUSA Pharma and AVEO Oncology Announce First Commercial Launch of FOTIVDA (tivozanib) | Nov 15 2017
HEMEL HEMPSTEAD, England & CAMBRIDGE, Massachusetts. – – EUSA Pharma and AVEO Oncology (NASDAQ: AVEO) today announced the first commercial launch of FOTIVDA® (tivozanib) with the initiation of product sales in Germany. In t... |
| 13.11.2017 | Grupo Biotoscana Acquires Laboratorio DOSA | Nov 13 2017
Montevideo, Uruguay - - GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, today announced the acquisition of Laboratorio DOSA S.A., a specialty pharmaceutical manufacturer based in Argenti... |
| 01.11.2017 | Biotoscana Announces Launch of ABRAXANE/ABRAXUS in Brazil and Mexico | Nov 01 2017
MONTEVIDEO, Uruguay—BIOTOSCANA INVESTMENTS S.A. (“Company” or “GBT”) (B3: GBIO33), a leading biopharmaceutical company in Latin America, announces to its shareholders and the market in general that it has launched ABRAXANE / A... |
| 18.10.2017 | AxoGen, Inc. Receives David J. Gury Company of the Year Award from BioFlorida | Oct 18 2017
ALACHUA, Florida (GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, has received the BioFlorida David J. Gury Company of the Yea... |
| 18.10.2017 | EW Healthcare Partners Announces the Appointment of Three Senior Executives | Oct 18 2017
NEW YORK, New York—EW Healthcare Partners (“EW”), a leading healthcare growth equity firm with a global investment practice, has announced the addition of three senior executives to their investment team:
• Lamberto Andreotti,... |
| 03.10.2017 | Grupo Biotoscana and EISAI Sign Licensing Agreement for Four Oncology & Neurology Products in LatAm | Oct 03 2017
MONTEVIDEO, Uruguay and WOODCLIFF LAKE, New Jersey—GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, today announced that it has entered into an exclusive licensing agreement with Eisai In... |
| 30.08.2017 | Grupo Biotoscana Expands Partnership with Gilead Sciences in HCV in Brazil | Aug 30 2017
Montevideo, Uruguay—GBT-Grupo Biotoscana (B3: GBIO33), a leading specialty pharmaceutical company in Latin America, today announced that it has expanded its partnership with Gilead Sciences (Nasdaq: GILD) in HCV in Brazil. Unde... |
| 02.08.2017 | AxoGen, Inc Reports 2017 Second Quarter Financial Results, Representing 46% Growth over Prior Year | Aug 02 2017
ALACHUA, Fla., (GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for t... |
| 27.07.2017 | Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year | Jul 27 2017
DANVERS, Massachusetts— Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2018 revenue of $132.5 million, an increase of 29% compared to revenue of ... |
| 21.07.2017 | Grupo Biotoscana Raises $417 Million in Oversubscribed Brazil IPO | Jul 21 2017
LONDON, United Kingdom—EW Healthcare Partners (“EWHP”), a global healthcare growth equity investor, announced that Grupo Biotoscana (“Biotoscana”), a Pan-Latin American specialty pharmaceutical company focused on oncology and c... |
| 13.07.2017 | Venus Concept Closes $38 Million Equity Financing to Support Continued Growth Opportunities | Jul 13 2017
TORONTO, Canada—Venus Concept Ltd., a privately-held and innovative global aesthetic technology leader, today announced the closing of a $38 million equity investment. The equity investment was led by EW Healthcare Partners alo... |
| 23.06.2017 | EUSA Pharma Receives Positive CHMP Opinion for Tivozanib for First-Line Treatment | Jun 23 2017
HEMEL HEMPSTEAD, England – – EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced that the European Medicines Agency’s Committee for Medicinal Products fo... |
| 17.05.2017 | Endologix Provides an Update on the Nellix Endovascular Aneurysm Sealing System US Regulatory Status | May 17 2017
IRVINE, California – Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that the Company met with the Food and Drug Administration (FDA) regarding its Nellix®... |
| 09.05.2017 | European Commission Approves the Only Immunotherapy for High-Risk Neuroblastoma | May 09 2017
HEMEL HEMPSTEAD, England – EUSA Pharma today announced that the European Commission (EC) has approved the antibody ch14.18/CHO, dinutuximab beta, for the treatment of high-risk neuroblastoma in patients aged 12 months and above... |
| 27.03.2017 | EUSA Pharma and Apeiron Biologics Receive Positive CHMP Opinion for Dinutuximab Beta | Mar 27 2017
HEMEL HEMPSTEAD, England and VIENNA, Austria – – EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, and Apeiron Biologics today announced that the European Medicines Ag... |
| 24.02.2017 | Xenex Secures $38 Million in Funding Led by Essex Woodlands & Piper Jaffray Merchant Banking | Feb 24 2017
SAN ANTONIO, Texas—Xenex Disinfection Services, the manufacturer of LightStrike Germ-Zapping Robots™, today announced the investment of $38 million in a funding round led by Essex Woodlands (EW), one of the country’s leading he... |
| 14.02.2017 | Endologix Completes Patient Enrollment in the Ovation LUCY Study | Feb 14 2017
IRVINE, California (GLOBE NEWSWIRE)—Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has completed patient enrollment in the LUCY (Evaluation of FemaLe... |
| 06.12.2016 | Prolacta Bioscience Raises $35 Million in Mezzanine Financing | Dec 06 2016
CITY OF INDUSTRY, California – Prolacta Bioscience®, the nation’s leading provider of human milk-based neonatal nutritional products, today announced the closing of a $35 million mezzanine round of financing. The transaction wa... |
| 05.12.2016 | Metabolon Raises Additional $15 Million in Funding from Essex Woodlands | Dec 05 2016
RESEARCH TRIANGLE PARK, N.C. – – Metabolon, Inc., the global leader in metabolomics, announced today that it has raised an additional $15 million in funding from investor Essex Woodlands, a leading healthcare growth equity firm... |
| 11.08.2016 | Metabolon Closes $15 Million Financing to Support Precision Medicine Growth Opportunities | Aug 11 2016
RESEARCH TRIANGLE PARK, N.C. –– Metabolon, Inc., the global leader in metabolomics, announced today that it has closed a financing that raised $15 million from new investor Essex Woodlands, a leading healthcare growth equity fi... |
| 25.07.2016 | Pierre Fabre Pharmaceuticals and Grupo Biotoscana enter into a Commercialization Agreement | Jul 25 2016
Castres (France) and Montevideo (Uruguay) – July 25, 2016 – Pierre Fabre Pharmaceuticals, the second-largest French private pharmaceutical laboratory and Grupo Biotoscana SL (GBT), a leading specialty pharmaceutical company in ... |
| 14.06.2016 | Suneva Medical Closes $25 Million Financing to Support Continued Growth Opportunities | Jun 14 2016
San Diego, CA (June 14, 2016)—Suneva Medical, Inc., a privately-held and innovative aesthetics leader, today announced the closing of a $25 million investment by Essex Woodlands. This financing strengthens Suneva Medical’s rapi... |
| 11.04.2016 | Endologix Announces CE Mark for Next-Generation Nellix(R) EndoVascular Aneurysm Sealing System | Apr 11 2016
IRVINE, California (GLOBE NEWSWIRE)—Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today achievement of CE (Conformite Europeenne) Mark of the next-generation Nell... |
| 07.04.2016 | ABIOMED Impella Therapy Receives FDA Approval for Cardiogenic Shock After Heart Attack/Heart Surgery | Apr 07 2016
DANVERS, Massachusetts – April 7, 2016 – Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that it has received U.S. Food and Drug Administration (FDA) Pre-Market Appro... |
| 30.03.2016 | AxoGen, Inc. Launches AcroVal Neurosensory and Motor Testing System | Mar 30 2016
ALACHUA, Florida - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the commercial release and first sale of AcroVal™ Neurosensory &a... |
| 08.03.2016 | Endologix Announces First Patients in Japan Treated with Nellix(R) EndoVascular Aneurysm System | Mar 08 2016
IRVINE, California (GLOBE NEWSWIRE)—Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the first two patients with abdominal aortic aneurysms (“AAAs”) in Ja... |
| 22.02.2016 | Corium Announces Positive Topline Results from Phase 1 Clinical Study | Feb 22 2016
MENLO PARK, California—Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced posi... |
| 04.02.2016 | Grupo Biotoscana Advances Integration of Laboratorio LKM | Feb 04 2016
MONTEVIDEO – – Grupo Biotoscana SL (GBT), a leading specialty pharmaceutical company in Latin America, today announced continued progress in its integration of Laboratorio LKM (LKM) with an enhanced organizational structure and... |
| 04.02.2016 | Abiomed Announces Q3 FY 2016 Revenue of $85.8 Million, Up 38% Over Prior Year | Feb 04 2016
DANVERS, Massachusetts—Abiomed (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today reported third quarter fiscal 2016 revenue of $85.8 million, an increase of 38% compared to revenue of $62.0 mi... |
| 03.02.2016 | Endologix, Inc. and TriVascular Technologies, Inc. Complete Merger | Feb 03 2016
IRVINE, California (GLOBE NEWSWIRE)—Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has successfully completed the previously announced merger with Tr... |
| 11.01.2016 | Abiomed Announces Preliminary Q3 FY 2016 Revenue of $85.8 Million, Up 38% Over Prior Year | Jan 11 2016
SAN FRANCISCO, CA.—Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today reported preliminary unaudited third quarter fiscal 2016 revenue of approximately $85.8 million, an increase ... |
| 21.12.2015 | Grupo Biotoscana acquires Laboratorio LKM | Dec 21 2015
MADRID AND BUENOS AIRES – Grupo Biotoscana SL, a leading specialty pharmaceutical company in Latin America, today announced that it has completed the acquisition of Laboratorio LKM S.A., a specialty pharmaceutical manufacturer ... |
| 26.10.2015 | Endologix, Inc. and TriVascular Technologies, Inc. Announce Merger | Oct 26 2015
IRVINE, California and SANTA ROSA, California—Endologix, Inc. (Nasdaq: ELGX) and TriVascular Technologies, Inc. (Nasdaq: TRIV) announced today that they have entered into a definitive merger agreement under which Endologix and ... |
| 27.08.2015 | Essex Woodlands Fund 1 Acquires Significant Position in AxoGen, Inc. | Aug 27 2015
ALACHUA, Florida—AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, has sold 4,861,111 registered shares of its common stock to Essex Woodlands, a lead... |
| 05.08.2015 | Corium Prices Follow-On Offering of Common Stock | Aug 05 2015
MENLO PARK, California (GLOBE NEWSWIRE)—Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, tod... |
| 04.08.2015 | Abiomed Announces Q1 FY 2016 Revenue of $73.4 Million, Up 50% Over Prior Year | Aug 04 2015
DANVERS, Massachusetts—Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2016 revenue of $73.4 million, an increase of 50% compared to revenue of $4... |
| 29.07.2015 | Corium Reports Third Quarter Fiscal 2015 Financial Results | Jul 29 2015
MENLO PARK, California—Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced una... |
